News
AbbVie's study also met all secondary goals, with 64.1% patients on Qulipta seeing a 50% or more reduction in the average ...
AbbVie said on Wednesday its migraine drug met the main goal and was superior to a generic drug in a head-to head late-stage ...
US pharma major AbbVie (NYSE: ABBV) today announced positive top-line results from its Phase III TEMPLE multicenter, ...
This was the stock's third consecutive day of losses.
19h
Zacks.com on MSNHere's Why AbbVie (ABBV) Fell More Than Broader MarketIn the most recent trading session, AbbVie (ABBV) closed at $185.48, indicating a -2.82% shift from the previous trading day.
3h
Stocktwits on MSNAbbVie’s Migraine Drug Yields Positive Outcome In Late-Stage Study Versus Topiramate, But Fails To Draw Retail CheerShares of AbbVie (ABBV) were in the spotlight on Wednesday after the company announced positive results from a late-stage ...
AbbVie (NYSE:ABBV) said on Wednesday that its late-stage study testing atogepant in comparison with the highest dose of ...
Two Democratic lawmakers have renewed accusations that large pharma companies have evaded paying U.S. taxes through a ...
Bavarian Nordic has sold a PRV for $160m, a day after the FDA announced a new scheme utilising the fast-track tickets.
The FDA approval of Vimkunya has given the chikungunya vaccine’s owner, Bavarian Nordic, an extra financial windfall. | The ...
SAN DIEGO, CA / ACCESS Newswire / June 18, 2025 / New endorsement signals growing momentum toward sustainability in pharmaceutical supply chains. My Green Lab®, the world's leading nonprofit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results